QSAMD News and Press, QSAM Biosciences Inc

New research has identified a molecule that is involved in both cardiovascular disease and cancer metastasis. For cancer to become malignant, cells in tumors undergo various transformations that involve interactions between the tumor and an individual’s immune system. While most o...

QSAM Biosciences (OTCQB: QSAM) is a company developing a new class of drugs called radiopharmaceuticals that deliver radiation therapy directly and specifically to cancer cells. The company’s lead drug candidate, CycloSam(R), is a clinical-stage bone-seeking radiopharmaceutical desi...

QSAM Biosciences (OTCQB: QSAM) , a clinical-stage biotechnology company, is focused on bringing to market targeted therapeutic radiopharmaceuticals. “The company is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment ...

Liver cancer is quite rare in children and teens, accounting for only 1% to 2% of pediatric cancers . Even so, it affects around two to three million minors , usually in the first three years of their lives. For the past couple of decades, experts have classified pediatric liver cancers as...

Scientists at the Lineberger Comprehensive Cancer Center, University of North Carolina have found that the OTUD7A gene impacts Ewing sarcoma development. Ewing sarcoma is a type of cancer that develops primarily in children and affects bones or tissues surrounding the bones. Figures show t...

QSAM Biosciences (OTCQB: QSAM) is a company developing next-generation targeted therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (“CycloSam(R)”), for the treatment of cancer and related diseases. The company today announced that the United States Patent & Tr...